-
Sihuan Pharmaceutical Reports H1 2023 Revenue Dip Amid R&D Focus
•
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its financial report for the first half of 2023, recording revenues of RMB 1.0557 billion (USD 144 million), marking a 27.9% decrease year-on-year (YOY). The research and development (R&D) expenses for the period were RMB 294 million (USD 40 million), a…
-
China Grand Pharmaceutical Reports H1 2023 Revenues and Pipeline Progress
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has released its financial report for the first half of 2023, highlighting strong revenue growth and significant advancements in its clinical pipeline. The company recorded revenues of HKD 5.989 billion (USD 766 million) and net profits of HKD 1.124 billion…
-
Lepu ScienTech Reports 33% Revenue Growth in 2023 Interim Report
•
Lepu ScienTech Medical Technology (Shanghai) Co., Ltd, (HKG: 2291) a China-based medical technology company, has released its 2023 interim report, showcasing significant financial growth. The company reported revenues of RMB 165.9 million, marking a 33.0% increase year-on-year (YOY). Net profits also saw a substantial rise, surging by 213.7% YOY to…
-
Simcere Pharmaceutical Reports 25.2% Revenue Growth in 2023 Interim Financials
•
China-based Simcere Pharmaceutical Group (HKG: 2096) has released its interim financial report for 2023, revealing a robust performance in the first half of the year. The company reported revenues of RMB 3.379 billion (USD 466 million), reflecting a 25.2% year-on-year (YOY) increase. Notably, sales of innovative drugs accounted for 71%…
-
3D Medicines’ H1 2023 Report Highlights 70.3% YOY Growth in Envafolimab Sales
•
China-based oncology specialist 3D Medicines (HKG: 1244) has released its financial report for the first half of 2023, highlighting significant revenue generated by envafolimab, a programmed death-ligand 1 (PD-L1) antibody capable of subcutaneous injection. The product has been covered under 32 city-level insurance schemes (HuiMinBao) and has seen rapid uptake,…
-
MicroPort Scientific Reports 19% Revenue Growth in H1 2023, Driven by Diverse Interventions
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its financial report for the first half of 2023, showcasing impressive revenue growth of 19% year-on-year (YOY) to USD 493 million. The company also reported a 13% reduction in losses, totaling USD 220 million. This performance highlights the company’s…
-
CanSino Biologics Reports H1 2023 Revenues Down 96.7% YOY, COVID-19 Demand Decreases
•
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has released its financial report for the first half of 2023, recording revenues of RMB 21.09 million (USD 2.89 million), a decrease of 96.7% year-on-year (YOY). The contributions from China and overseas markets were RMB 17.93 million and RMB 3.16 million, respectively. The…
-
Sandoz Reports H1 2023 Financials with 8% YOY Growth, Separation from Novartis Looms
•
Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the first half of 2023, ahead of its scheduled separation from parent company Novartis (NYSE: NVS) on October 4 this year. The subsidiary reported USD 4.8 billion in sales for the period, marking an 8% year-on-year (YOY) expansion in constant…
-
Junshi Biosciences Reports H1 2023 Revenue Dip Amid Commercial Success and R&D Focus
•
China’s Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial report for the first half of 2023, recording RMB 670 million (USD 91.9 million) in revenues, a 29.21% year-on-year (YOY) decrease, primarily due to decreased licensing income. Despite this, commercialized products generated RMB 625 million (USD 85.8 million), marking…
-
Lee’s Pharmaceutical Holdings Ltd Reports H1 2023 Revenue Dip Amid Product Portfolio Growth
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its financial report for the first half of 2023, recording revenues of HKD 512 million (USD 65.2 million), marking a year-on-year (YOY) decrease of 21.1%. The decline is primarily attributed to product rights expiration, falling sales volumes, and the devaluation of…
-
Johnson & Johnson Reports H1 2023 Sales Growth Following Kenvue Spinoff
•
Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has released a financial update for the first half of 2023, following the completion of the separation of its consumer healthcare spinoff, Kenvue (NYSE: KVUE), into an independent company. The document reveals that H1 2023 global sales reached USD 42.4 billion,…
-
Zhejiang Dian Diagnostics Reports 2023H1 Revenue Dip, Strategic Expansion Continues
•
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has released its financial report for the first half of 2023, recording revenues of RMB 6.842 billion (USD 938.7 million), marking a year-on-year (YOY) decrease of 36.37%. Net profits were reported at RMB 453 million, reflecting a significant YOY decrease of 75.89%.…
-
Luye Pharma Group Reports H1 2023 Revenue Growth with Strong Oncology and CNS Sales
•
China-based Luye Pharma Group (HKG: 2186) has announced its financial performance for the first half of 2023, along with recent business updates. The group reported overall revenues of RMB 2.904 billion (USD 399.7 million), with product sales contributing RMB 2.785 billion (USD 383.3 million), marking an 18.7% year-on-year (YOY) increase.…
-
Lundbeck A/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales
•
Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has released its financial report for the H1 2023 period, reporting a 10% year-on-year (YOY) increase in sales revenues in constant exchange rate terms, reaching DKK 10 billion (USD 1.45 billion) over the six-month period. CEO Deborah Dunsire celebrated the “excellent performance,”…
-
Harbour BioMed Reports First Profitable Half-Year in H1 2023 Financial Results
•
China-based Harbour BioMed (HKG: 2142) has released its interim financial report for the first half of 2023, recording revenues of USD 40 million and nearly USD 3 million in profits, marking the company’s first profitable half-year. This financial success is attributed to a licensing agreement focused on batoclimab (HBM9161) and…
-
Luye Pharma Group’s Subsidiary Boan Biotechnology Reports 18.4% Revenue Growth in H1 2023
•
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955), has announced its financial report for the first half of 2023, along with key business updates. The company reported revenues of RMB 261 million (USD 29.8 million) for the period, marking an 18.4% year-on-year (YOY)…
-
3SBio Inc. Reports H1 2023 Revenue Growth and Expansion in Digital Marketing
•
China-based 3SBio Inc. (HKG: 1530) has released its financial report for the first half of 2023, recording revenues of RMB 3.784 billion (USD 521 million), marking a 22.3% year-on-year (YOY) increase. Net profits reached RMB 1.191 billion, up 20.1% YOY. Product Sales and Market Share HighlightsTPIAO (recombinant human thrombopoietin [rhTPO]),…
-
Innovent Biologics Reports 20.6% YOY Revenue Growth in H1 2023 Financials
•
China-based Innovent Biologics Inc., (HKG: 1801) has released its financial results for the first half of 2023, reporting a total revenue of RMB 2.7 billion (USD 374 million), marking a 20.6% year-on-year (YOY) increase. The actual product sales contributed RMB 2.458 billion (USD 340 million) to the total, also up…
-
WuXi Biologics Reports 17.8% Revenue Growth and Expands Service Scope in H1 2023
•
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has released its unaudited interim financial report for the period ended June 30, 2023. The report indicates a 17.8% year-on-year (YOY) increase in revenues, reaching RMB 8.49 billion (USD 1.17 billion). This growth is attributed to the successful…
-
Everest Medicines Reports Q1 2023 Revenue Growth and Pipeline Progress
•
China-based Everest Medicines (HKG: 1952) has announced its financial and corporate update for the first half of 2023. The company reported a revenue increase of RMB 7.9 million, reaching RMB 8.9 million (USD 1.23 million) for the six-month period. This growth was primarily attributed to the sales of Xerava and…
